PHILADELPHIA, March 18, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announces its financial results for the fiscal year ended December 31, 2007. The net loss for the year (including non-cash charges) was approximately $18,139,000 or ($0.25) per share compared to a loss of $19,399,000 or ($0.31) per share in 2006. This $1,260,000 decrease in loss was primarily due to: 1) higher interest and other income of approximately $646,000 basically due to more funds being available for investing in marketable securities, 2) lower interest and financing costs relating to our convertible debentures that were retired completely in June, 2007 and 3) a gain of $346,000 in other income relating to penalties accrued for liquidating damages with respect to convertible debentures that were settled without charge at maturity.
